Form 4: Cabaletta Bio Director Receives Stock Option Grant

Director Richard C. Henriques Jr. was granted 22,000 stock options in Cabaletta Bio, Inc. as part of standard equity compensation.

Summary

• Director Richard C. Henriques Jr. received a grant of 22,000 stock options for Cabaletta Bio, Inc. (CABA) common stock.
• The options have an exercise price of $3.22 per share.
• The grant was issued on June 9, 2026, with an expiration date of June 8, 2036.
• The options vest in full on the earlier of June 9, 2027, or the date of the next annual stockholders' meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $3.22 exercise price.

Future Outlook

The options vest in one year, indicating a standard retention and incentive structure for board members.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board alignment with company performance.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical compensation packages for directors in small-cap biotech firms.

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of options on June 9, 2027, or the next annual meeting.

Key Dates

Keywords

Cabaletta Bio, CABA, Director Compensation, Stock Options, Insider Transaction, SEC Form 4